Metastatic Prostate Cancer (Copay) now open at Patient Advocate Foundation Co-Pay Relief.
Prostate Cancer (Copay) now open at Patient Advocate Foundation Co-Pay Relief.
First Data Release from The Metastatic Prostate Cancer Project
ARAMIS Trial Finds That the Investigational Treatment Darolutamide Extends Metastasis-free Survival of Men with M0 Castrate Resistant Prostate Cancer
It has been announced that the Phase III ARAMIS Trial (Androgen Receptor inhibiting Agent for Metastatic-free Survival) evaluating an investigational treatment known as darolutamide in men with Non-metastatic Castration-resistant Prostate Cancer (nM0) has successfully met its primary endpoint of extending the metastasis-free survival (MFS) of men compared to placebo.
Ablative Radiation Increases Survival in Some Newly Diagnosed Men with Metastatic Prostate Cancer
Castration Levels and ADT
FDA Accepts A New Endpoint
More Radium is Not Better
African American Men Might Have a Survival Advantage Over Caucasian Men!
177Lu-PSMA-617 Clinical Trials
Endocyte, Inc. announced that it has enrolled the first man into its phase 3 VISION study of 177Lu-PSMA-617 as a clinical therapy. Cancer ABCs has had a number of men asking about the trial.
VISION is an open-label, randomized trial assessing the addition of radiolabeled prostate-specific membrane antigen to standard therapy for PSMA-positive, previously treated metastatic castration-resistant prostate cancer (mCRPC). The study will enroll 750 men in total, with the primary endpoint being overall survival.
Currently, there are six different trials evaluating 177Lu-PSMA-617 actively recruiting men worldwide. In the United States they are at Weill Cornell Medical Center in New York, UCLA in Los Angles, and one site in Houston Texas. There are also trials in multiple locations in the UK, in Italy and in Australia. For additional trial information and locations go to
https://clinicaltrials.gov/ct2/results?term=177Lu-PSMA-617&Search=Search
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.
Treatments for Advanced Prostate Cancer May Work Better in Black Men
Black men are more likely to be diagnosed with prostate cancer at a younger age, with an advanced stage, and with a higher grade. Black men are also twice as likely to die from prostate cancer than white men. Despite these facts, these two studies show that certain treatments for advanced metastatic prostate cancer may work better in black men.
A Generic Version of Zytiga Has Been Approved by the FDA
The U.S. Food and Drug Administration (FDA) has approved a generic version of Zytiga, the new drug’s name is Yonsa. It is a novel formulation of abiraterone acetate that needs to be used in combination with methylprednisolone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
